Quantcast
Indoor Mold Can Be Very Dangerous For Asthma Sufferers

Indoor Mold Can Be Very Dangerous For Asthma Sufferers

Rayshell Clapper for redOrbit.com - Your Universe Online The allergen and fungi mold is gross. It looks gross in its variety of colors. It grows in typically gross places (around toilet bowls, under sinks, in nooks and crannies). It feels gross...

Latest asthma Stories

2014-09-02 08:29:36

MONROVIA, Calif., Sept. 2, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Debra Zack, M.D., Ph.D., vice president, clinical development and the appointment of Lloyd Rowland, senior vice president, chief compliance officer and general counsel. "Debra's expertise in biologics...

2014-09-02 04:21:24

QXFORD, England, September 2, 2014 /PRNewswire/ -- Triggers milestone payment from Mylan Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces that its Marketing Authorisation Application (MAA) for PSX1001 has been validated and is being assessed under the Decentralised Procedure (DCP), in which the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) is...

2014-08-21 12:25:49

Efficacy on Reducing Exacerbations and Hospitalizations is One of the Key Drug Attributes for Formulary Inclusion, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 21, 2014 /PRNewswire/ -- Decision Resources Group finds that the asthma market in Brazil and Mexico currently faces severe coverage restrictions. The uptake of several newly approved agents, the anticipated label extension of Boehringer Ingelheim/Pfizer's Spiriva for this indication and the launch of...

2014-08-20 16:25:21

LONDON, Aug. 20, 2014 /PRNewswire/ -- GlaxoSmithKline plc today announced that the FDA has approved Arnuity(TM) Ellipta(®) (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Arnuity is not indicated for relief of acute bronchospasm. The approved doses are Arnuity Ellipta 100mcg and 200mcg. Arnuity Ellipta is administered once daily via the dry...

2014-08-19 16:29:04

VIENNA, Va., Aug. 19, 2014 /PRNewswire-USNewswire/ -- Children with asthma and food allergies are vulnerable to bullying at school and online, often by classmates who tease or harass them because they're "different." It may be an age-old problem, but it must be addressed if we expect kids to be able to focus on their studies. Stopping confrontations before they start creates an environment where all children feel protected. "The keys to preventing bullying are self-confidence and...

2014-08-19 12:28:32

For U.S. Media Only RIDGEFIELD, Conn., Aug. 19, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for the fixed-dose combination (FDC) of tiotropium and olodaterol delivered via the Respimat(®) inhaler for the proposed indication of long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including...

2014-08-13 08:28:16

Two New States Named to the 2014 Asthma and Allergy School Honor Roll During a Record Year for Medication Access, but More Still Needs to Be Done. WASHINGTON, Aug. 13, 2014 /PRNewswire-USNewswire/ -- In just a few weeks, schools will be back in session for the millions of students with asthma and food allergies. So what are schools doing to protect students and teachers with these chronic diseases? Today the Asthma and Allergy Foundation of America (AAFA) revealed its 2014 State Honor...

2014-08-06 12:28:26

Microneedle Patches and Subcutaneous Implants Offer Significant Revenue Potential, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 6, 2014 /PRNewswire/ -- Decision Resources Group finds that the United States drug delivery device market will grow at a strong rate to reach a value of over $4.5 billion by 2022 (including device costs only). The future of the drug delivery device market is highly dependent on the pharma industry. Because certain types of drugs are...

2014-08-05 08:33:53

MONROVIA, Calif., Aug. 5, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that John Desjarlais, Ph.D., senior vice president, research and chief scientific officer, will present at the Wedbush Securities 2014 Life Sciences Management Access Conference on Tuesday, August 12, 2014 at 3:40 p.m. EDT in...

2014-08-01 08:26:18

For U.S. Media Only RIDGEFIELD, Conn., Aug. 1, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved Striverdi(®) Respimat(®) (olodaterol) Inhalation Spray 5 mcg as a long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. STRIVERDI RESPIMAT is not indicated to treat acute...


Latest asthma Reference Libraries

Journal of Allergy and Clinical Immunology
2012-05-14 11:51:18

The Journal of Allergy and Clinical Immunology is a medical journal established in 1929 as the Journal of Allergy. It is published by Elsevier. It obtained its current name in 1971. It is the official journal of the American Academy of Allergy, Asthma and Immunology. This journal publishes timely clinical papers, instructive case reports, and detailed examinations of state-of-the-art equipment and techniques to clinical allergists, immunologists, dermatologists, internists, and other...

More Articles (1 articles) »
Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'